Nyrada -NYR-BI03 Phase Ia Clinical Trial Update – Correction

Highlights:
•Nyrada is scheduled to submit its regulatory package to Human Research Ethics Committee (HREC) for review before the end of 2024.
•Updated Phase Ia study design now includes five randomised, placebo-controlled cohorts of eight healthy human volunteers receiving single ascending doses.
•HREC review to be conducted in January 2025, allowing volunteer recruitment to commence thereafter with dosing expected to be complete in July 2025.
•Final Phase Ia trial results expected in 3QCY20263QCY2025.